Find Clinical Trials

Inclusion Criteria: * Healthy male or female participants aged 18 to 65 years, inclusive. * Participants have a body mass index (BMI) of 18 to 35 kg/m2, inclusive. * Participants are able and willing to give written informed consent, adhere to the compliance terms during participation in the study, undergo the examinations and testing set forth in the study Protocol and clearly and reliably communicate their subjective symptoms to the Investigator. * Part 2 Only: Patient has a diagnosis of MDD and is not on antidepressant medication. Exclusion Criteria: * Current, or history (within the last 6 months) of, alcohol or substance use disorder. * Use of pharmacological compounds for psychiatric or neurological conditions acting on the CNS within 30 days or 5 half-lives (whichever is longer) prior to Screening. * Current or clinically relevant history of schizophrenia, psychotic, bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder or panic disorder. * In first-degree relatives, a history of schizophrenia, psychosis, bipolar disorder, delusional disorder, paranoid personality disorder or schizoaffective disorder. * History of a diagnosis of Hallucinogen Persistent Perceptual Disorder (HPPD). * Significant suicide risk. * Other personal circumstances and behavior that is incompatible with establishment of rapport or safe exposure to psilocin, as judged by the Investigator. * Part 1 Only: Ongoing current MDD, or history of MDD within the last year.

Inclusion Criteria: From the Hammersmith Hospital In-patient Cardiology Services: * Adults aged \>18 years * Known or newly diagnosed type 2 diabetes * Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and/or insulin * Admitted to Hammersmith Hospital cardiology inpatient services with ACS * Raised blood troponin level on admission From Imperial College Healthcare Trust Diabetes and Cardiology Clinics: * Adults aged \>18 years * Known type 2 diabetes * Previous acute coronary syndrome within the last 10 years but \> 6 months ago * Taking one or more oral hypoglycaemic agent and /or GLP1 receptor analogue, and/or insulin Exclusion Criteria: From the Hammersmith Hospital In-patient Cardiology Services: * HbA1c \<48mmol/mol * People who have previously had bariatric surgery * People taking hydroxyurea * People who undergo haemodialysis or peritoneal dialysis * Unable to participate due to other factors, as assessed by the Chief Investigators * Pregnancy as determined by clinical team * Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year From Imperial College Healthcare Trust Diabetes and Cardiology Clinics: * HbA1c \<48mmol/mol * People who have previously had bariatric surgery * People taking hydroxyurea * People who undergo haemodialysis or peritoneal dialysis * Unable to participate due to other factors, as assessed by the Chief Investigators * Pregnancy as determined by clinical team * Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year * Previous acute coronary syndrome more than 10 years ago or within the last 6 months Withdrawal criteria * The subject has a serious event related to the study * Investigated initiated discontinuation of study due to participation or equipment concerns * Withdrawal of consent

Inclusion Criteria: * Kidney transplant recipient aged 18 or greater * Post-transplant months 2-12 * eGFR \>= 20 mL/min * Have at least one of the following: 1. Hypertension history (BP \>= 150/90 or on BP medications) 2. Hyperglycemia history (FBG \>= 100 x 2 or on diabetes medications) 3. Overweight (BMI \>= 25) Exclusion Criteria: * Rejection episode before study enrollment * Gastrointestinal feeding tube or requires alternative nutrition * Unable to understand or read English * Unable to attend online classes or complete study questionnaires independently * Already eating a plant-based diet * Unwilling to make dietary changes * Pregnant or breastfeeding * Unable to consent * Blindness * Prisoners

Inclusion Criteria: 1. Women aged 18 or older. 2. Patients with a French health insurance coverage (having a French social security number). 3. Patient eligible for free flap reconstruction surgery of the breastunder general anaesthesia. 4. Patient who has given written consent to participate in accordance with the regulations. 5. Having a negative blood pregnancy test for patients of childbea ring age. Exclusion Criteria: 1. Allergy or intolerance to any of the drugs (dexmedetomidine, remifentanil, lidocaine, propofol, dexamethasone, kétamine, ketoprofen, nefopam, paracetamol, morphine, ropivacaine, droperidol, ondansetron). 2. Known history of heart failure, arrhythmias and/or ischemic heart disease and/or severe renal insufficiency. 3. Pulse below 50bpm during anaesthesia consultation and/or under beta blocker treatment. 4. Treatment with ACEI/ARB. 5. Severe asthma. 6. Symptomatic gastric or duodenal ulcer with or without treatment. 7. Baseline systolic blood pressure \< 100 mmHg. 8. Chronic preoperative pain and/or use of WHO ladder step 2 or 3 analgesics preoperatively. 9. Patient already included in another therapeutic trial evaluating an experimental molecule. 10. Persons deprived of liberty or under guardianship. 11. Patients with suspected difficulties in assessing pain on a scale. 12. Inability to undergo trial medical monitoring due to geographic, social or psychological reasons.

Inclusion Criteria: * Adolescents of 12 to 17 years old. * Diagnosis of exogen obesity with a body mass index (BMI) greater than percentile 95 for age and sex, according to the Center for Disease Control and Prevention (CDC) graphics, that precedes the diagnosis of asthma. * Plasmatic concentration of 25-hydroxyvitamin D less than 30 ng/ml at screening visit based on local laboratory test. * Physician-diagnosed asthma, with more than 6 months of evolution, based on medical history, physical examination, clinical criteria according to the Global Initiative For Asthma 2020 (GINA) and confirmed with a spirometry with reversibility after the administration of a bronchodilator. * Asthma severity (intermittent or mild persistent or moderate persistent) according to the National Asthma Education and Prevention Program (NAEPP) and classified as controlled, partly controlled or uncontrolled according to GINA 2020. * Negative allergic skin tests. Exclusion Criteria: * History of systemic or chronic degenerative disease (renal, pulmonar, cardiovascular, infectious, muscular, immunological, hypertension, diabetes mellitus, cancer, nonalcoholic fatty liver disease). * Current treatment with immunomodulators or immunostimulants, up to 6 months before the intervention. * History of adverse effects to vitamin D. * Treatment with oral steroids 3 months previous to the enrollment. * Active smoking. Elimination criteria: * Parents, tutors, legal guardians or participants that decide to withdraw from the study any time. * Pregnancy during study. * Severe adverse effects to vitamin D.

Participant Inclusion Criteria for interviews and focus group discussions (Aims 1 and 2): * Breast cancer survivor, patient advocate or key healthcare personnel * Key healthcare personnel are defined as hospital and laboratory leaders, pathologists, laboratory scientists and technicians, oncologists, nurses, and surgeons, with: * \>12 months of employment at the affiliated institution * Administrative or clinical involvement in the delivery of breast cancer care services. * Age 18 years and above * Permanent residents or citizens of Tanzania * Participant and/or LAR willing and able to consent * Fluent in Swahili and/or English by self-report Participant Exclusion Criteria: * Key stakeholder not residing at their particular institutions during data collection will be excluded. Eligibility criteria for Chart Reviews (Aim 1) Inclusion Criteria for chart review: * Age 18 years and above * Permanent residents or citizens of Tanzania * Received breast cancer diagnosis Exclusion Criteria for chart review: * Participants less than 18 years of age

Inclusion Criteria: Meets American Diabetes Association (ADA) criteria for diabetic retinopathy screening: * Diagnosis of Type 1 diabetes for ≥3 years, and age 11 or in puberty * Diagnosis of Type 2 diabetes Enriched cohort: * Patients with Type 1 or Type 2 diabetes, * 8-21 years of age with known diabetic retinopathy (true positives). * No time limit on last diabetic eye exam. Exclusion Criteria: * Known diabetic eye exam in the last 12 months

Inclusion Criteria: 1. Diagnosis of open angle glaucoma (Primary open angle glaucoma, Pseudoexfoliation glaucoma, Pigmentary dispersion glaucoma) 2. Clinically eligible for both surgeries (Trabeculectomy and XEN) on the discretion of the surgeon (area of healthy, free and mobile conjunctiva in the superior nasal target quadrant) 3. VA logMAR ≤ 1 (VA dec ≥ 0.1) 4. Trabecular meshwork must be visible (with Shaffer angle grade \> 1 in the target quadrant) 5. Age 18 years or older 6. Patient understands the nature of the procedure, is willing to comply with associated follow-up evaluations, and provides written informed consent Exclusion Criteria: 1. Clinical significant cataract 2. Subject has had prior cataract surgery in study eye ≤ 1 months (count to operation) 3. Subject has had prior (incisional) glaucoma surgery (XEN, trabeculectomy, viscocanalostomy, canaloplasty, shunts of any type, collagen implants, etc.). Prior iridotomy is acceptable. 4. Phacic Angle Closure Glaucoma 5. Subject has neovascular, uveitic or angle recession glaucoma or any glaucoma associated with vascular disorders 6. Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis) 7. Anterior chamber intraocular lens 8. Vitreous present in the anterior chamber 9. Presence of intraocular silicone oil 10. History of corneal surgery, corneal opacities, or corneal disease 11. Impaired episcleral venous drainage (e.g. Sturge-Weber or nanophthalmos) 12. History of dermatologic keloid formation 13. Active diabetic retinopathy, proliferative retinopathy, choroidal neovascularization, branch retinal vein occlusion, central retinal vein occlusion, or other ophthalmic disease or disorder that could confound study results 14. Known or suspected allergy or sensitivity to drugs required for the surgical procedure or any of the device components (e.g., porcine products or glutaraldehyde), 15. Pregnant or nursing women

Inclusion Criteria 1. be ≥ 40 and \<70 years old at time of US 2. No history of previous breast cancer including DCIS 3. have dense breasts (BI-RADS category C and D on mammography performed within 12 months of breast US) and negative/benign BI-RADS assessment categories on mammography (BI-RADS 1, 2) 4. undergoing screening breast US using either automated or handheld device Exclusion Criteria 1. history of bilateral prophylactic mastectomy 2. history of bilateral foreign body injection 3. history of bilateral breast implants 4. history of bilateral breast reduction surgery or surgical excision 5. currently pregnant or breast feeding in the preceding 6 months 6. Known distant metastasis from other primary cancer

Inclusion Criteria: * Subject is already implanted with a Moderato IPG that can be used to deliver CNT pacing signals, whether CNT pacing was activated or not. * Subject is willing and able to comply with the study and procedures. Exclusion Criteria: * Subject is dependent on 100% ventricular pacing. * Subject has symptoms of heart failure, NYHA Class III or greater. * Subject has an ejection fraction of 25% or less * Subject's systolic blood pressure is less than 100 mm Hg on the day of recording. * Subject has decompensated heart failure * Subject has significant (\>3+) mitral regurgitation, aortic regurgitation, or aortic stenosis * Subject has permanent atrial fibrillation. * Subject has Atrial fibrillation on the day of the study. * Subject has hypertrophic cardiomyopathy, restrictive cardiomyopathy, or interventricular septal thickness ≥15 mm. * Subject is on dialysis * Subject has prior neurological events (stroke or TIA) within the past year or a neurological event (stroke) at any prior time that has resulted in residual neurologic deficit. * Subject has a history of autonomic dysfunction. * Women who are pregnant or breast-feeding. * Subject cannot or is unwilling to provide informed consent

Inclusion criteria: * ≥ 18 years old * Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations. * Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted. * WHO Functional Class I-III * Ambulatory * Able to have an MRI/MRS, perform a 6MWD test, and cardiopulmonary exercise test Exclusion criteria: * Pregnancy * Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins * WHO Functional class IV heart failure * Requirement for continuous oxygen * Unable to have an MRI/MRS, perform a 6MWD test, or cardiopulmonary exercise test. * Patients with implanted/embedded ferromagnetic material that would preclude cardiac MRI

Inclusion Criteria: Female age ≥ 18 Women undergoing mastectomy and immediate one-stage mesh assisted implant breast reconstruction as standard treatment Exclusion Criteria: Revision reconstruction surgery Delayed reconstruction surgery

Inclusion Criteria: * English-speaking * U.S. Military Veterans * endorse depression (Patient Health Questionnaire-depression score \> 10) * endorse insomnia (Insomnia Severity Index score \> 10). Exclusion Criteria are limited in accordance with real world effectiveness trials, but will include: * pregnancy * history of bipolar disorder * history of psychosis * current use of anti-psychotic medications or mood stabilizers (e.g., lithium) * current suicidal ideation with active intent

Inclusion Criteria: * Aged \>=18 years; * Pregnancy woman; * With a singleton pregnancy; * Volunteer and receive regular antenatal examinations in the research centers; * Volunteer to sign a written informed consent. Exclusion Criteria: * Concurrent with hypertension, diabetes, liver and kidney diseases, hematonosis and other serious diseases of pre-pregnancy women, including patients requiring long-term medication for primary diseases; * With history of preeclampsia; * Tumor patients concurrent with serious infection requiring long-term drug treatment; * Pregnant women conceiving through in vitro fertilization; * Multiple pregnancies; * Patients with clear indications of medical pregnancy termination during early pregnancy; * Any medical or non-medical conditions deemed inappropriate for study participation according to the investigator.

Inclusion Criteria: * Signed the informed consent form; * Women aged ≥ 18 years; * Patients with locally advanced or metastatic, histologically or cytologically documented breast cancer; * The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative; * Eastern Cooperative Oncology Group (ECOG) score \[0-1\] points; * Patients must have metastatic disease that is evaluable on imaging: including at least one measurable lesion (assessed according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)); or only non-measurable disease as defined by RECIST 1.1 , especially in patients with bone metastases only, while the disease could be documented/assessed by bone scan, PET or MRI; * Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomization; * No previous chemotherapy for advanced breast cancer ; * For HR+ breast cancer patients shall meet one of the two criteria below: a) radiographically confirmed recurrence or progression within 2 years of adjuvant endocrine therapy; b) received at least one line of endocrine therapy in the recurrence or metastasis stage; * Patients must have recovered to ≤ Grade 1 (CTCAE v5.0) from all toxicities related to prior antineoplastic therapy. However, patients with any grade of alopecia were allowed ; * Patients with asymptomatic CNS metastases may be enrolled, if: 1. Intracranial lesions are evaluable and eligible for systemic therapy only in the absence of extracranial evaluable lesions, or 2. Patients with stable intracranial lesions after local treatment while there are extracranial evaluable lesions ; * Adequate hematological, hepatic and renal function; * Women of childbearing potential must agree to use a contraceptive method during the treatment period and for at least 90 days after the last dose of experiment treatment; * Life expectancy of at least 12 weeks; * Patients must be able to participate and comply with treatment and follow up. Exclusion Criteria: * HER-2 positive (IHC 3+, or FISH positive); * Other malignancies (including primary brain or leptomeninges-related tumors) within the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ; * Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy; * Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first dose of treatment, or anticipating for a major surgical procedure during the study; * Experienced grade ≥ 3 nervous system-related adverse events after treatment with anti-microtubule drugs; * Symptomatic central nervous system metastases; * Pregnant or lactating women; * Known or suspected hypersensitivity to any of the study drugs or excipients; * Any other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that precludes study treatment implementation or follow-up ; * Any other condition that the investigator considers inappropriate to participate in this trial . * Use of corticosteroids is prohibited.

Inclusion Criteria: 1. Female and male patients ≥18 years 2. WHO/NYHA functional class II - IV 3. PH with HFpEF diagnosed by right heart catheterisation showing: mean pulmonary arterial pressure (mPAP) ≥25mmHg at rest; pulmonary arterial wedge pressure (PAWP) ≥15mmHg at rest or LVEDP ≥16mmHg and/or PAWP≥25 mmHg during exercise, and 4. Preserved left ventricular ejection fraction ≥50% 5. Patients receiving optimized therapy including intensified treatment with diuretics and who have been stable for 1 month before entering the study. 6. Except for diuretics, medical treatment should not be changed during the study period. 7. Able to understand and willing to sign the Informed Consent Form Exclusion Criteria: 1. Pre-capillary pulmonary hypertension (Group I; Group III; Group IV; Group V according to PH guidelines) 2. Congenital or acquired severe valvular diseases (severe aortic stenosis or insufficiency, severe mitral valve stenosis or insufficiency) 3. Pregnancy or lactation 4. Walking disability 5. Subject who participates in an interventional study during the course of this study 6. Severe lung disease: FEV1/FVC \<0.5 and total lung capacity \<60% of the normal value 7. Active myocarditis, unstable angina pectoris, exercise induced ventricular arrhythmias, active liver disease, porphyria or elevations of serum transaminases \>3 x ULN (upper limit of normal) or bilirubin \>1.5 x ULN 8. Haemoglobin concentration less than 75% of the lower limit of normal 9. Systolic blood pressure \<85 mmHg 10. History or suspicion of inability to cooperate adequately.

Inclusion Criteria: * Youth/family has contacted a participating outpatient clinic to seek mental health care, and is placed on the waitlist. * Youth is between the ages of 9-17 years (inclusive) at the time of study enrollment. * Youth and at least one guardian consent to the youth's participation in study. * Youth reads English well enough to effectively complete the digital programs (defined as taking classes in English, as opposed to ESL classes). * Youth has access to a digital device. Exclusion Criteria: * Youth is non-English speaking, as the program is only available in English. * Youth does not have access to a digital device.

Inclusion criteria: * Participants must have the following criteria: * oligomenorrhea-anovulation * spontaneous intermenstrual periods (if not on hormonal birth control or birth control that alters menstrual cycle timing) of \< 21 days or \> 35 days or a total of 8 or fewer menses per year * if on hormonal birth control or birth control that alters menstrual cycle timing, a history of irregular periods * and hyperandrogenism * If not on hormonal birth control or birth control that alters menstrual cycle timing: Total testosterone ≥ 35 ng/dL OR free testosterone \> 4.0 pg/ml OR free androgen index \> 1.5 OR in-person scoring for hirsutism, based on the modified Ferriman-Gallwey score, if attending an in-person assessment or based on the self-assessment (if not attending an in-person assessment) with a score of ≥ 4 considered hirsutism; * If on hormonal birth control or birth control that alters menstrual cycle timing: Tests within the past 10 years showing the above or study team's in-person assessment of hirsutism as above. * If no medical records to confirm (most recent test from within the last 10 years in range), tests for diagnosis will be ordered: * total testosterone \< 100 ng/dL, * dehydroepiandrosterone sulfate (DHEAS) \< 600 μg/dL, * fasting 17-hydroxyprogesterone (17-OHP) level \< 2.0 ng/mL, * prolactin \< 25 ng/ml), * follicle-stimulating hormone (FSH) levels \< 20 mIU/mL * BMI 25-50 kg/m2 or 23-50 kg/m2 for Asians * Access to internet * Ability to engage in light physical activity * Willingness to be randomized to either dietary approach * Measured HbA1c at baseline of 5.3%-9.0% Exclusion criteria: * Primary * Patients with non-PCOS etiologies of anovulation and hyperandrogenism (Cushing's disease, thyroid dysfunction, elevated prolactin levels, signs of a congenital adrenal hyperplasia organic intracranial lesion like a pituitary tumor, or suspected adrenal or ovarian tumor secreting androgens) * Menopause or removal of the ovaries * history of type 1 diabetes * use of medications prescribed for weight loss or psychostimulants known to affect weight * participation in another weight loss program or intervention * use of glucose lowering medications other than metformin or medications known to affect metabolism, such as chronic oral corticosteroids * pregnant or planning to become pregnant during the intervention period * Breastfeeding or less than 6 months postpartum * previous bariatric surgery or planning to have bariatric surgery during the study period * Self-reported blood disorders that influence HbA1c, including frequent blood transfusions, phlebotomy, anemia, hemoglobinopathy, and polycythemia * Ability * inability to read, write, or speak English * inability to provide informed consent * adherence to a vegan or vegetarian diet * difficulty chewing or swallowing * no influence over what foods are purchased, prepared, and/or served or inability to follow dietary advice due to lack of money or other resources * above weight limit (500 lbs) for DEXA * self-report of alcohol or substance use disorder within the past 5 years, including current at-risk drinking based on an AUDIT score of 15 or higher (but those who score a 15 or higher and have this criterion as their only reason for ineligibility may be assessed by a clinical psychologist for alcohol use disorder and if deemed to not have such a disorder would be eligible for the trial) * Safety * Renal disease: BUN \> 30 mg/dL or serum creatinine \> 1.4 mg/dL in our screening blood tests or history of kidney stones * untreated eating disorder or unstable serious mental illness (such as depression (score of 20 or greater on the PHQ8), bipolar or schizophrenia with psychosis) * use of warfarin * chronic kidney disease, stage 4 or higher * Any other concerning values in baseline labs (we will plan to send the participant to their PCP and allow the participant to return for later enrollment if labs are no longer concerning) Examples: * triglycerides of 600 mg/dL or higher * baseline uncorrected thyroid disease: TSH \< .45 mIU/ML or \> 4.5 mIU/ML * potassium: any abnormal value * baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 times normal * any condition for which the study team deems participation to be unsafe or inappropriate

Inclusion Criteria: * Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type): 1-Hereditary risk for cancer including * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing) * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia) * Hereditary Cancer Prediction Model-based elevated cancer risk * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\&N cancer for example), etc. * Exposed High Risk including * Childhood cancer survivors with treatment exposures associated with increased risk of cancer * Adult cancer survivors with treatment exposures associated with increased risk of cancer * Documented high level exposure to group 1 IARC carcinogens * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \>50, Smoking history of \>15 pack years, First-degree relative history of lung cancer or COPD * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis * Precursor Lesions including * Breast: ductal/lobular carcinoma in situ (CIS) and atypical hyperplasia * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia/adenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia/carcinoma in situ, * Lung: Adenomatous hyperplasia * H\&N: high-risk oral precancerous diseases * Skin: Class II melanocytic lesions. Squamous dysplasia * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas * Thoracic: Lung nodules detected on screening CT that prompt further follow-up * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others. * FAMILY MEMBERS or healthy individuals Exclusion Criteria: There are no exclusion criteria for the study. Note: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.

Inclusion Criteria: * Female biological sex at birth * \>18 years * Diagnosis of stage I, II, or III breast cancer * starting neoadjuvant or adjuvant intravenous chemotherapy * ECOG \<3; * Oncologist approval to participate; * English speaking (all study materials and study staff will be in English) * Willing and able to adhere to study intervention Exclusion Criteria: * Individuals who do not have access to a smart phone with Bluetooth capability (required for Fitbit and for responding to intervention text messages) or at least a shared cell phone with someone in the same household (i.e., some couples may share a phone). * Type 1 or type 2 diabetes who require exogenous insulin (due to the potential need to adjust insulin dosing with TRE) or with hemoglobin A1c \>10% * Research MRI contraindications (e.g., pacemaker, magnetic implants, pregnancy) * Uncontrolled thyroid disorder * Self-reported eating disorder history * Body mass index \<18.5 kg/m2 or clinical signs of cachexia (discretion of treating oncologist) * ≥5% body weight loss within last 6 months * Those who are currently working night/rotating shifts, eating within ≤10-hour window or consistently eating less than 3 meals/day in the past 3 months. * patients who meet the criteria for medical clearance prior to exercise using the Physical Activity Readiness Questionnaire+ and are not cleared by their treating oncologist or family physician to perform maximal exercise testing.